本研究は、様々な種類の癌（固形腫瘍）患者におけるBI 905677の安全な投与量を特定し、試験することを目的としている。

基本情報

NCT ID

NCT03604445

ステータス

中止

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

37

治験依頼者名

Boehringer Ingelheim

概要

This study is open to adults with different types of advanced cancer (solid tumours). This study is open to people in whom previous treatments were not successful. The purpose of this study is to find out the highest dose of BI 905677 the participants can tolerate. BI 905677 is a type of an antibody that is being developed to treat cancer. One dose of BI 905677 is given to the participants every 2 or 3 weeks as infusion into a vein. In this study, BI 905677 is given to humans for the first time. The participants visit the study site at least once a week so that the doctors can check their general health. The participants are in the study for as long as they benefit from and can tolerate treatment.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)